Urinary multi-omics reveal non-invasive diagnostic biomarkers in clear cell renal cell carcinoma

Gustav Jonsson,Maura Hofmann,Tiago Oliveira,Ursula Lemberger,Karel Stejskal,Gabriela Krššáková,Irma Sakic,Maria Novatchkova,Stefan Mereiter,Gerlinde Grabmann,Thomas Köcher,Zeljko Kikic,Gerald N. Rechberger,Thomas Züllig,Bernhard Englinger,Manuela Schmidinger,Josef M. Penninger

DOI: https://doi.org/10.1101/2024.08.12.607453

2024-09-09

Abstract:Clear cell renal cell carcinoma (ccRCC) is the kidney malignancy with the highest incidence and mortality rates. Despite the high patient burden, there are no biomarkers for rapid diagnosis and public health surveillance. Urine would be an ideal source of ccRCC biomarkers due to the low invasiveness, easy accessibility, and the kidney’s intrinsic role in filtering urine. In the present work, by combining proteomics, lipidomics and metabolomics, we detected urogenital metabolic dysregulation in ccRCC patients with increased lipid metabolism, altered mitochondrial respiration signatures and increased urinary lipid content. Importantly, we identify three early-stage diagnostic biomarkers for ccRCC in urine samples: Serum amyloid A1 (SAA1), Haptoglobin (HP) and Lipocalin 15 (LCN15). We further implemented a parallel reaction monitoring mass spectrometry protocol for rapid and sensitive detection of SAA1, HP and LCN15 and combined all three proteins into a diagnostic UrineScore. In our discovery cohort, this score had a performance accuracy of 96% in receiver operating characteristic curve (ROC) analysis for classification of ccRCC versus control cases. Our data identifies tractable and highly efficacious urinary biomarkers for ccRCC diagnosis and serve as a first step towards the development of more rapid and accessible urinary diagnostic platforms.

Cancer Biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to find non - invasive diagnostic biomarkers for clear cell renal cell carcinoma (ccRCC). Specifically, by combining proteomics, lipidomics and metabolomics methods, the authors detected metabolic abnormalities in the urine of ccRCC patients and discovered three early - diagnosis biomarkers from them: serum amyloid A1 (SAA1), haptoglobin (HP) and lipocalin 15 (LCN15). These findings provide a rapid and non - invasive method for the early diagnosis of ccRCC, which helps to improve the survival rate and quality of life of patients.

### Main research contents:
1. **Multi - omics analysis**:
- **Proteomics**: Through proteomics analysis of urine sediment and supernatant, metabolic abnormalities in the urine of ccRCC patients were found, especially the increase in lipid metabolism and mitochondrial respiratory chain activity.
- **Metabolomics**: Untargeted metabolomics analysis showed that certain metabolites in the urine of ccRCC patients were significantly reduced, especially in the aspartate, alanine and glutamate metabolic pathways.
- **Lipidomics**: Lipidomics analysis showed that the levels of coenzyme Q10, phosphatidylcholine (PCs) and phosphatidylethanolamine (PEs) in the urine of ccRCC patients were significantly increased.

2. **Identification of biomarkers**:
- Through the above multi - omics analysis, the authors identified three potential early - diagnosis biomarkers: SAA1, HP and LCN15.
- The expression of these biomarkers in the urine of ccRCC patients was significantly higher than that in the control group.

3. **Parallel reaction monitoring mass spectrometry (PRM - MS)**:
- In order to achieve rapid and highly sensitive detection, the authors developed a PRM - MS method for the quantitative detection of SAA1, HP and LCN15.
- Combining the PRM scores of these three proteins, the authors proposed a comprehensive UrineScore for distinguishing ccRCC patients from healthy control groups.

### Research significance:
- **Non - invasive diagnosis**: Urine, as a sample source, has the characteristics of low invasiveness and easy access, and is suitable for large - scale population screening.
- **Early diagnosis**: Early diagnosis is crucial for improving the survival rate and treatment effect of ccRCC patients.
- **High accuracy**: UrineScore shows 96% high accuracy in distinguishing ccRCC patients from healthy control groups, showing its potential in clinical applications.

In conclusion, through multi - omics analysis, this study successfully identified three potential early - diagnosis biomarkers for ccRCC and developed a rapid, highly sensitive detection method, providing new ideas and tools for the early diagnosis of ccRCC.